Mumbai, Sept 16: Ranbaxy Laboratories, India's largest pharmaceutical company, received approval from the US Food and Drug Administration to market an orally disintegrating tablet form of the cephalexin antibiotic drug on Tuesday. The new dosage form, developed under Ranbaxy's novel drug delivery system programme will be sold under the brand name Panixine DisperDose, it said in a statement.

The US FDA approval is for tablets in the 125 mg and 250 mg strengths. The tablets for oral suspension are a generic form of Keflex made by Ceph International.
The total market for cephalexin made in the United States was valued at $148 million in the 12 months to June. Bureau Report